ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(19)30027-0
◽
2019
◽
Vol 20
(6)
◽
pp. 849-861
◽
Cited By ~ 74
Author(s):
Cathy Eng
◽
Tae Won Kim
◽
Johanna Bendell
◽
Guillem Argilés
◽
Niall C Tebbutt
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Related Documents
Cited By
References
Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO
SSRN Electronic Journal
◽
10.2139/ssrn.3478102
◽
2019
◽
Author(s):
Chiara Cremolini
◽
Carlotta Antoniotti
◽
Daniele Rossini
◽
Sara Lonardi
◽
Fotios Loupakis
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(19)30862-9
◽
2020
◽
Vol 21
(4)
◽
pp. 497-507
◽
Cited By ~ 28
Author(s):
Chiara Cremolini
◽
Carlotta Antoniotti
◽
Daniele Rossini
◽
Sara Lonardi
◽
Fotios Loupakis
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.726215272.793539632
◽
2017
◽
Author(s):
Patrick Nana-Sinkam
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Small Cell
◽
Phase 2
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
The Lancet
◽
10.1016/s0140-6736(19)30723-8
◽
2019
◽
Vol 393
(10189)
◽
pp. 2404-2415
◽
Cited By ~ 233
Author(s):
Brian I Rini
◽
Thomas Powles
◽
Michael B Atkins
◽
Bernard Escudier
◽
David F McDermott
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Randomised Controlled Trial
◽
Cell Carcinoma
◽
Metastatic Renal Cell Carcinoma
◽
Renal Cell
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet
◽
10.1016/s0140-6736(16)32517-x
◽
2017
◽
Vol 389
(10066)
◽
pp. 255-265
◽
Cited By ~ 1731
Author(s):
Achim Rittmeyer
◽
Fabrice Barlesi
◽
Daniel Waterkamp
◽
Keunchil Park
◽
Fortunato Ciardiello
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Small Cell Lung Cancer
◽
Controlled Trial
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Phase 3
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
The Lancet
◽
10.1016/s0140-6736(14)62004-3
◽
2015
◽
Vol 385
(9980)
◽
pp. 1843-1852
◽
Cited By ~ 254
Author(s):
Lieke H J Simkens
◽
Harm van Tinteren
◽
Anne May
◽
Albert J ten Tije
◽
Geert-Jan M Creemers
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Maintenance Treatment
◽
Controlled Trial
◽
Phase 3
◽
Cancer Group
◽
Randomised Controlled
Download Full-text
Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Global Health
◽
10.1016/s2214-109x(19)30427-9
◽
2019
◽
Vol 7
(12)
◽
pp. e1706-e1716
◽
Cited By ~ 6
Author(s):
Sutapa B Neogi
◽
Niveditha Devasenapathy
◽
Ranjana Singh
◽
Himanshu Bhushan
◽
Duru Shah
◽
...
Keyword(s):
Randomised Controlled Trial
◽
Pregnant Women
◽
Controlled Trial
◽
Intravenous Iron
◽
Severe Anaemia
◽
Iron Sucrose
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.717950273.793455532
◽
2012
◽
Author(s):
Alexander Eggermont
Keyword(s):
Randomised Controlled Trial
◽
Metastatic Melanoma
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial
The Lancet Gastroenterology & Hepatology
◽
10.1016/s2468-1253(18)30269-3
◽
2018
◽
Vol 3
(12)
◽
pp. 845-855
◽
Cited By ~ 5
Author(s):
Alvaro Romera
◽
Sergiy Peredpaya
◽
Yaroslav Shparyk
◽
Igor Bondarenko
◽
Giovanni Mendonça Bariani
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Controlled Trial
◽
Line Treatment
◽
First Line
◽
Open Label
◽
Randomised Controlled
◽
First Line Treatment
Download Full-text
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(20)30452-6
◽
2020
◽
Vol 21
(10)
◽
pp. 1317-1330
◽
Cited By ~ 3
Author(s):
Shaji K Kumar
◽
Susanna J Jacobus
◽
Adam D Cohen
◽
Matthias Weiss
◽
Natalie Callander
◽
...
Keyword(s):
Multiple Myeloma
◽
Stem Cell
◽
Randomised Controlled Trial
◽
Stem Cell Transplantation
◽
Controlled Trial
◽
Newly Diagnosed
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Randomised Controlled
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close